 SVB Leerink initiated Selecta Biosciences Inc NASDAQ: SELB coverage with an Outperform rating and a price target of 7. The analysts view ImmTORs approach to mitigate ADAs as de-risked by early clinical data from SEL-212 and believe that the ability to tame the immune. 